Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Article in English | MEDLINE | ID: mdl-14565232

ABSTRACT

Human telomerase is a reverse transcriptase that is expressed in essentially all cancer cells, but not in the vast majority of normal somatic cells. Therefore, the specific inhibition of telomerase activity in tumors might have significant beneficial therapeutic effects. We have designed and evaluated oligonucleotide N3' --> P5' thio-phosphoramidates as telomerase template antagonists. In biochemical cell-free assays 11-13-mer thio-phosphoramidate oligonucleotides demonstrated sequence specific and dose dependent inhibition of telomerase with pico-molar IC50 values. Optimization of the oligonucleotide sequence and length resulted in the identification of a 13-mer-oligonucleotide thio-phosphoramidate GRN163 as a drug development candidate. In cell cultures GRN163 was able to inhibit telomerase activity in the absence of cationic lipid with approximately 1 microM IC50 values. Telomerase inhibition by GRN163 produced gradual telomere shortening, followed by cellular senescence and/or apoptosis of cancer derived cell lines.


Subject(s)
Antineoplastic Agents/chemical synthesis , Cell Survival/drug effects , Oligonucleotides/pharmacology , Phosphates/pharmacology , Telomerase/antagonists & inhibitors , Templates, Genetic , Antineoplastic Agents/pharmacology , Base Sequence , Drug Design , Humans , Oligonucleotides/chemical synthesis , Oligonucleotides/chemistry , Phosphates/chemistry , Tumor Cells, Cultured
2.
Article in English | MEDLINE | ID: mdl-14565482

ABSTRACT

A series of oligonucleotide conjugates were designed and synthesized as novel inhibitors of human telomerase. These compounds contain a relatively short (6-7-mer) oligonucleotide domain, with an N3'-->P5' phosphoramidate (np) or thio-phosphoramidate (nps) backbone, targeted to the template region of the RNA component of the enzyme and various pendant groups attached to either their 5'- or preferably to the 3'-termini. The most potent compounds in the series inhibited telomerase with low nM IC50 values in biochemical assays whereas the cognate oligonucleotides without the pendant groups were significantly less active having IC50 values 100-1000-fold higher.


Subject(s)
Enzyme Inhibitors/chemical synthesis , Oligodeoxyribonucleotides/chemical synthesis , Telomerase/antagonists & inhibitors , Amides , Base Sequence , Enzyme Inhibitors/pharmacology , Fluorescent Dyes , Humans , Oligodeoxyribonucleotides/pharmacology , Phosphoric Acids , Structure-Activity Relationship
3.
Cancer Res ; 63(14): 3931-9, 2003 Jul 15.
Article in English | MEDLINE | ID: mdl-12873987

ABSTRACT

Telomerase, the enzyme responsible for proliferative immortality, is expressed in essentially all cancer cells, but not in most normal human cells. Thus, specific telomerase inhibition is potentially a universal anticancer therapy with few side effects. We designed N3'-->P5' thio-phosphoramidate (NPS) oligonucleotides as telomerase template antagonists and found that their ability to form stable duplexes with the telomerase RNA subunit was the key factor for antitelomerase activity. In biochemical assays 11-13-mer NPS oligonucleotides demonstrated sequence- and dose-dependent inhibition of telomerase with IC(50) values <1 nM. Optimization of the sequence, length, and bioavailability resulted in the selection of a 13-mer NPS oligonucleotide, GRN163, as a drug development candidate. GRN163 inhibited telomerase in a cell-free assay at 45 +/- 7 pM, and in various tumor cell lines at approximately 1 nM and approximately 0.3-1.0 micro M in the presence and absence of carriers, respectively. GRN163 was competitive with telomeric primer binding, primarily because of hybridization to human telomerase RNA (hTR) component. Tumor cells treated with GRN163 in culture underwent telomere shortening, followed by cellular senescence or apoptosis after a period of time that generally correlated with initial telomere length. In a flank DU145 (prostate cancer) xenograft model, parenterally administered GRN163 caused suppression of tumor growth in the absence of gross toxicity. These data demonstrate that GRN163 has significant potential for additional development as an anticancer agent.


Subject(s)
Oligonucleotides/pharmacology , Telomerase/antagonists & inhibitors , Amides/metabolism , Amides/pharmacology , Biological Availability , Cell Survival/drug effects , Dose-Response Relationship, Drug , Humans , Oligonucleotides/genetics , Oligonucleotides/metabolism , Oligonucleotides/pharmacokinetics , Phosphoric Acids/metabolism , Phosphoric Acids/pharmacology , RNA/genetics , RNA/metabolism , Telomerase/genetics , Telomerase/metabolism
4.
Biochemistry ; 42(2): 589-600, 2003 Jan 21.
Article in English | MEDLINE | ID: mdl-12525188

ABSTRACT

Telomerase is a ribonucleoprotein responsible for maintaining the ends of linear chromosomes in nearly all eukaryotic cells. In humans, expression of the enzyme is limited primarily to the germ line and progenitor cell populations. In the absence of telomerase activity, telomeres shorten with each cell division until a critical length is reached, which can result in the cessation of cell division. The enzyme is required for cell immortality, and its activity has been detected in the vast majority of human tumors. Because of this, telomerase is an attractive target for inhibition in anticancer therapy. To learn more about the biochemistry of the human enzyme and its substrate recognition, we have examined the binding properties of single-stranded oligonucleotide primers that serve as telomerase substrates in vitro. We have used highly purified human enzyme and employed a two-primer method for determining the dissociation rates of these primers. Primers having sequence permutations of (TTAGGG)(3) were found to have considerably different affinities. They had t(1/2) values that ranged from 14 min to greater than 1200 min at room temperature. A primer ending in the GGG register formed the most stable complex with the enzyme. This particular register imparted stability to a nontelomeric primer resulting in a nearly 100-fold decrease in the k(off). We have found that interactions of telomerase with primer substrates are stabilized mainly by contacts with the protein subunit of the enzyme (hTERT). Base-pairing between the primer and the template region of telomerase contributes minimally to its stabilization.


Subject(s)
DNA Primers/chemistry , Telomerase/chemistry , Binding, Competitive , Catalytic Domain , Cell Line , DNA Primers/genetics , Enzyme Stability , Guanosine/analogs & derivatives , Guanosine/chemistry , Guanosine/genetics , Humans , Kinetics , Mutation , RNA/chemistry , Substrate Specificity , Telomerase/isolation & purification , Templates, Genetic
5.
Nucleic Acids Res ; 30(2): 559-68, 2002 Jan 15.
Article in English | MEDLINE | ID: mdl-11788719

ABSTRACT

Telomerase is a ribonucleoprotein responsible for maintaining telomeres in nearly all eukaryotic cells. The enzyme is able to utilize a short segment of its RNA subunit as the template for the reverse transcription of d(TTAGGG) repeats onto the ends of human chromosomes. Transfection with telomerase was shown to confer immortality on several types of human cells. Moreover, telomerase activation appears to be one of the key events required for malignant transformation of normal cells. Inhibition of telomerase activity in transformed cells results in the cessation of cell proliferation in cultures and provides the rationale for the selection of telomerase as a target for anticancer therapy. Using oligonucleotide N3'-->P5' phosphoramidates (NPs) we have identified a region of the human telomerase RNA subunit (hTR) approximately 100 nt downstream from the template region whose structural integrity appears crucial for telomerase enzymatic activity. The oligonucleotides targeted to this segment of hTR are potent and specific inhibitors of telomerase activity in biochemical assays. Mutant telomerase, in which 3 nt of hTR were not complementary to a 15 nt NP, was found to be refractory to inhibition by that oligonucleotide. We also demonstrated that the binding of NP, oligonucleotides to this hTR allosteric site results in a marked decrease in the affinity of a telomerase substrate (single-stranded DNA primer) for the enzyme.


Subject(s)
Allosteric Site , Amides/metabolism , Oligonucleotides/metabolism , Phosphoric Acids/metabolism , RNA/antagonists & inhibitors , Telomerase/antagonists & inhibitors , Allosteric Regulation , Animals , Base Sequence , COS Cells , Cell Line , DNA Primers/genetics , DNA Primers/metabolism , DNA, Single-Stranded/genetics , DNA, Single-Stranded/metabolism , DNA-Binding Proteins , Humans , Inhibitory Concentration 50 , Kinetics , Molecular Sequence Data , Mutation/genetics , Nucleic Acid Conformation , Oligonucleotides/genetics , Oligonucleotides, Antisense/genetics , Oligonucleotides, Antisense/metabolism , RNA/chemistry , RNA/genetics , RNA/metabolism , Recombinant Proteins/antagonists & inhibitors , Recombinant Proteins/metabolism , Telomerase/chemistry , Telomerase/genetics , Telomerase/metabolism , Templates, Genetic , Thermodynamics
SELECTION OF CITATIONS
SEARCH DETAIL
...